logo
  

Karyopharm Therapeutics Inc. Q1 Loss increases, but beats estimates

Karyopharm Therapeutics Inc. (KPTI) revealed Loss for its first quarter that increased from the same period last year but beat the Street estimates.

The company's earnings came in at -$37.36 million, or -$0.32 per share. This compares with -$34.13 million, or -$0.30 per share, in last year's first quarter.

Analysts on average had expected the company to earn -$0.33 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.

The company's revenue for the quarter fell 14.4% to $33.13 million from $38.70 million last year.

Karyopharm Therapeutics Inc. earnings at a glance (GAAP) :

-Earnings (Q1): -$37.36 Mln. vs. -$34.13 Mln. last year.
-EPS (Q1): -$0.32 vs. -$0.30 last year.
-Revenue (Q1): $33.13 Mln vs. $38.70 Mln last year.

-Guidance:
Full year revenue guidance: $140 Mln-$160 Mln

For comments and feedback contact: editorial@rttnews.com

Minutes of the latest Fed policy session dominated the economics scene this week. Find out what made policymakers give a “higher for longer” signal on interest rates. In Europe, the main news out this week was the inflation print from the U.K. Learn how the data was bad news for those hoping for an imminent rate cut from the Bank of England. Also, explore why New Zealand's central bank also hinted at a delay in its plans for interest rate reduction in future.

View More Videos
RELATED NEWS
Follow RTT